Class of Stock [Axis] Series F Preferred Stock [Member] Equity Components [Axis] Common Stock [Member] Preferred Stock [Member] Subscription Receivable Preferred Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Option Exchange Agreement [Member] Exchange Agreement [Member] Pre-funded Warrant [Member] Legal Entity [Axis] Sanovas Ophthalmology LLC [Member] Sale of Stock [Axis] Private Placement [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Antidilutive Securities [Axis] Stock Options [Member] Warrant [Member] Related Party [Axis] Sanovas Ophthalmology LLC [Member] Original Employment Agreement [Member] Mr. Gerrans [Member] Amended and Restated Employment Agreement [Member] Halo Management LLC [Member] Title of Individual [Axis] Holders [Member] Plan Name [Axis] 2017 Equity Incentive Plan [Member] Statistical Measurement [Axis] Maximum [Member] Minimum [Member] Consulting Firm [Member] Award Type [Axis] Measurement Input Type [Axis] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Term [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Dividend Rate [Member] Fair Value Common Stock [Member] Exercise Price Range [Axis] Exercise Price 1 [Member] Exercise Price 2 [Member] Short-Term Debt, Type [Axis] Notes Payable, Other Payables [Member] Tax Period [Axis] No Expiration Date [Member] Expire in 2034 [Member] Sanovas Opthalmology [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current Assets Cash Due from Sanovas Deferred offering costs Total Current Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ DEFICIT Liabilities Current Liabilities Accounts Payable and accrued liabilities Due to Sanovas Due to officer Stockholders’ loans payable Accrued Interest Payable Total Liabilities Stockholders’ Deficit: Preferred stock, $0.0001 par value; 40,000,000 shares authorized; Series F preferred stock - 3,000,000 shares designated, 0 issued and outstanding at March 31, 2022 and December 31, 2021 Common stock, $0.0001 par value; 80,000,000 shares authorized; 14,282,314 shares issued and outstanding at March 31, 2022 and 14,221,814 shares issued and outstanding at December 31, 2021 Additional paid in capital Preferred stock subscription receivable Accumulated deficit Total Stockholders’ deficit TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT Statement [Table] Statement [Line Items] Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares designated Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Expenses General and Administrative Expenses Research and Development Stock-based compensation Total Expenses Interest expense Net Loss Net Loss per share - basic and diluted Weighted average number of common shares outstanding during the period- basic and diluted Balance Balance, shares Stock purchased by investors Stock purchased by investors, shares Stock based compensation Exercise of warrants Exercise of warrants, shares Retirement of due to Sanovas through the issuance of shares of common stock to Sanovas Ophthalmology LLC Retirement of due to Sanovas through the issuance of shares of common stock to Sanovas Ophthalmology LLC, shares Exchange of shares owned by Sanovas Ophthalmology LLC for pre-funded warrants Exchange of shares owned by Sanovas Ophthalmology LLC for pre-funded warrants, shares Recission of preferred stock Recission of preferred stock, shares Deferred costs Net loss Balance Balance, shares Statement of Stockholders' Equity [Abstract] Net of Deferred costs Statement of Cash Flows [Abstract] Cash Flows From Operating Activities Net Loss Adjustments to reconcile net loss to net cash used in operating activities Stock based compensation expense Increase in current assets Expenses paid by Sanovas on behalf of Company, net Increase in accounts payable and accrued liabilities (Increase) decrease in deferred offering costs Increase in accrued interest Total adjustments Net cash used in operating activities Cash Flows From Financing Activities Proceeds from common stock sold, net of costs Proceeds from exercise of warrants Advances from officer Decrease in stockholders’ refund payable Net cash provided by financing activities Net increase (decrease) in cash Cash at beginning of period Cash at end of period Supplemental information: Retirement of due to Sanovas through the issuance of common stock to Sanovas Ophthalmology LLC (Note C) Exchange of common stock by Sanovas Ophthalomology LLC for pre-funded warrants Accounting Policies [Abstract] HISTORY, BUSINESS PURPOSE, LIQUIDITY AND GOING CONCERN SIGNIFICANT ACCOUNTING POLICIES Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Equity [Abstract] COMMON AND PREFERRED STOCK Stock Plan STOCK PLAN Warrants WARRANTS Debt Disclosure [Abstract] NOTES PAYABLE Income Tax Disclosure [Abstract] INCOME TAXES Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Cash Equivalents Deferred Offering Costs Use of Estimates Income Taxes Income (Loss) Per Common Share Stock-based compensation Research and Development costs Recent Accounting Pronouncements Offering Costs SCHEDULE OF RELATED PARTY TRANSACTIONS SCHEDULE OF STOCK OPTION ACTIVITY SCHEDULE OF STOCK OPTIONS OUTSTANDING AND EXERCISABLE SCHEDULE OF STOCK OPTIONS FAIR VALUE ASSUMPTIONS SCHEDULE OF WARRANTS FAIR VALUE ASSUMPTIONS SCHEDULE OF WARRANTS ACTIVITY SCHEDULE OF WARRANTS OUTSTANDING Percentage of option to purchase of common stock Common stock, shares exchange Warrant, shares exchanged Warrant exercise price Retained Earnings (Accumulated Deficit) Proceeds from Issuance of Private Placement Repayments of Related Party Debt Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Unrecognized tax benefits Accrued penalties and interest Antidilutive securities excluded from computation of earnings per share Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Balance due from Sanovas – beginning of year Costs paid by Sanovas on the Company’s behalf Costs of Sanovas allocated to the Company Repayment of amounts charged by Sanovas, net Subtotal Retirement of due to Sanovas through the issuance of 390,358 and 358,126 shares of common stock in 2021 and 2020, respectively, to Sanovas Ophthalmology Balance due to (from) Sanovas - end of year Balance due from Sanovas – beginning of period Proceeds from (repayment of) costs charged by Sanovas to the Company, net Balance due to Sanovas - end of period Number of issuance of shares due to retirement Related party cost Value of shares issuance to offset due amounts Due to officer Schedule of Stock by Class [Table] Class of Stock [Line Items] Number of restricted shares issued Percentage of shares issued Number of shares issued during period Rescind, shares Shares issued price per share Sale of stock, shares issued Preferred stock, voting right Preferred stock, dividend Preferred stock, conversion price Proceeds from issuance of preferred stock Schedule Of Stock Option Activity Stock Options, Outstanding, Beginning Balance Weighted average exercise price, beginning balance Stock Options, Granted Weighted average exercise price, granted Stock Options, Canceled Weighted average exercise price, canceled Stock Options, Exercised Weighted average exercise price, exercised Stock Options, Outstanding, Ending Balance Weighted average exercise price, ending balance Stock Options, Outstanding, Ending Balance Weighted average exercise price, ending balance Schedule Of Stock Options Outstanding And Exercisable Exercise price Number of options, outstanding Weighted average remaining contractual life Number of options, exercisable Risk-free interest rates Expected life in years Expected volatility Expected dividend yield Fair value common stock Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common stock shares reserved for future issuance Number of stock options to purchase common stock Exercise price Options, vesting period Aggregate fair value of stock options Stock-based compensation expense Unrecognized compensation expense Weighted-average period for recognition Fair value of share price Fair value of option grant price per share Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair value common stock Expected life in years Schedule Of Warrants Activity Stock warrants issued, beginning balance Weighted average exercise price, beginning balance Warrants issued, granted Weighted average exercise price, granted Warrants issued, canceled Weighted average exercise price, canceled Warrants issued, exercised Weighted average exercise price, exercised Stock warrants issued, ending balance Weighted average exercise price, ending balance Stock warrants issued, ending balance Weighted average exercise price, ending balance Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Exercise price Number outstanding Weighted average remaining contractual life Number exercisable Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Warrants, term Warrants estimated fair value Exercisable, exercise price per shares Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Debt instrument, face amount Interest Rate Maturity Date Accrued interest Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards, Limitations on Use Operating loss carryforwards Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Assets, Operating Loss Carryforwards Deferred tax assets applicable to accruals Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Subsequent Event [Table] Subsequent Event [Line Items] Proceeds from sale of stock Number of shares sold during the period Discharge amount Option Exchange Agreement [Member]. Sanovas Ophthalmology LLC [Member]. Stock Options [Member]. Subscription Receivable Preferred Stock [Member] Deferred Offering Costs [PolicyText Block] Shares issued for repayment of debt value. Stock issued during period value retirement. Stock issued during period shares retirement. Sanovas Ophthalmology LLC [Member] Stock issued during period value for exchange of shares. Stock issued during period value for recission of preferred stock. Original Employment Agreement [Member]. Mr. Gerrans [Member] Amended and Restated Employment Agreement [Member]. Halo Management LLC [Member] Shares issued for repayment of debt shares. 2017 Equity Incentive Plan [Member]. Stock issued during period shares for exchange of shares. Stock issued during period shares for recission of preferred stock. Change in stockholders refund payable. LLC for prefunded warrants. Preferred stock shares designated. Consulting Firm [Member] Number of common stock shares exchanged. Due to related parties. Due to related parties gross. Stock Plan Disclosure [Text Block]. Fair value of share price. Warrants Disclosure [Text Block]. No Expiration Date [Member] Expire in 2034 [Member] Exercisable exercise price per share. Deferred tax assets applicable to accruals. Share based compensation arrangement by share based payment award non-options outstanding weighted average exercise price. Share based compensation arrangement by share based payment award non-options outstanding weighted average exercise price granted. Share based compensation arrangement by share based payment award non-options outstanding weighted average exercise price cancelled. Share based compensation arrangement by share based payment award non-options outstanding weighted average exercise price exercised. Schedule Of Warrant Outstanding [Table Text Block] Exercise Price 1 [Member] Exercise Price 2 [Member] Share based compensation arrangement by share based payment award other than options exercisable number. Exchange Agreement [Member] Holders [Member] Pre-funded Warrant [Member] Fair Value Common Stock [Member] Increase in accrued interest payable. Adjustment deferred costs. Offering Cost [Policy Text Block] Increase decrease in deferred assets Sanovas Ophthalmology LLC [Member] [Default Label] Assets, Current Assets Liabilities [Default Label] Preferred Stock, Shares Subscribed but Unissued, Subscriptions Receivable Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Shares, Outstanding Increase (Decrease) in Operating Assets IncreaseDecreaseInDeferredAssets Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Operating Activities ChangeInStockholdersRefundPayable Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations LLCForPrefundedWarrants Compensation Related Costs, Policy [Policy Text Block] DueToRelatedParties Proceeds from (Repayments of) Related Party Debt Due to Officers or Stockholders Warrants and Rights Outstanding, Measurement Input ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceGranted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceCancelled Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePriceExercised Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms